Colleagues,

Please find below the National Notifiable Diseases Surveillance System (NNDSS) Modernization Initiative (NMI) Technical Assistance (TA) Coordination Team Update for February 13, 2015. These e-mail updates are a collaboration among the Centers for Disease Control and Prevention (CDC), Council of State and Territorial Epidemiologists (CSTE), and the Association of Public Health Laboratories (APHL) and will be sent biweekly in an effort to keep reporting jurisdictions and other partners and stakeholders updated on the progress of NMI.

For more information on NMI, please see the NMI FAQs at http://wwwn.cdc.gov/nndss/script/faqs.aspx. If you have questions not answered in the FAQs, please send them to edx@cdc.gov.

**Message Mapping Guide Development Updates**

- The MMG Standardization Workgroup reviewed and incorporated, as appropriate, the feedback that APHL provided regarding the revised Generic v2 MMG, test scenarios, and test messages and the revised Hepatitis core and Hepatitis A MMGs using the new HL7 message structure.
- For the “Methods for Conveying Unknown or Missing Values in Case Notification Messages,” the MMG Development Team
  - expects to post the final document on the Draft MMG Web site in February 2015 and
  - has incorporated the indicators into the MMGs and will post the revised MMGs on the Draft MMG Web site as soon as possible.

**Message Mapping Guide Status Updates:**

- **Mumps and Pertussis MMGs (Stage I—Draft Phase):**
  - The MMG Development Team has incorporated unknown/missing indicators and revised the Mumps and Pertussis MMGs to reflect the new HL7 message structure.
  - The team expects to post the revised guides in March 2015 for a second external review period of approximately 4 weeks.

- **Congenital Syphilis and STD MMGs (Stage II—Reconciled Draft Phase):**
  - The MMG Development Team has incorporated unknown/missing indicators and revised the STD and Congenital Syphilis MMGs to reflect the new HL7 message structure.
The team delivered the restructured STD MMG to the MVPS Team on 2/6/2015 and will update the test messages and test scenarios as needed.

The MMG Development Team expects to deliver the restructured Congenital Syphilis MMG to the MVPS Team in February 2015 and, afterwards, will update the test messages and test scenarios as needed.

The MMG Development Team will post the STD and Congenital Syphilis MMGs as soon as possible as Stage III—Pilot Test-ready Draft Phase versions of the MMGs, along with their artifacts.

- **Generic v2 and Hepatitis MMGs** (Stage III—Pilot Test-ready Draft Phase)
  - The MMG Development Team has revised the Generic v2 MMG, test scenarios, and test messages to reflect the new HL7 message structure (incorporating core lab and vaccine variables).
  - The team has incorporated unknown/missing indicators and revised the Hepatitis MMG, test scenarios, and test messages to reflect the new HL7 message structure.
  - The team delivered the restructured Generic v2 and Hepatitis MMGs to the MVPS Team on 2/6/2015 and will update the test messages and test scenarios as needed.
  - The MMG Development Team expects to post updated versions of the Generic v2 and Hepatitis artifacts to the Draft MMG Web site in February 2015.

- No guides are in Stage IV—Final MMG Phase at this time.

### Message Validation, Processing, and Provisioning System Updates

- **Role-Based Security Updates:**
  - In early February 2015, the MVPS Team worked with AgileX to finalize requirements for MVPS role-based dashboard security that were submitted to AgileX at the end of January 2015. Role-based security will give users external to CDC the ability to access the MVPS software.

- **Development for Message Processing in Support of Message Restructuring Updates:**
  - The MVPS Team continues to work on the message restructuring requirements documents, expected to be delivered to AgileX in mid-February 2015.
  - When the message restructuring is completed, MVPS and METS will be updated to reflect the new message structure and associated processing changes.
  - Along with the METS tool, MVPS system functionality is expected to be available to begin validation testing with the jurisdictions by June 2015.

### Technical Assistance Updates

- On January 29, 2015, the NMI Technical Assistance Coordination Team (CDC, CSTE, and APHL) held a conference call with NMI pilot states Michigan, Oregon, New York, and Minnesota, who have been the initial participants in the first phase of NMI Technical Assistance. During the call, the team discussed the changes in the new HL7 message structure and outlined a draft time line for technical assistance.

- The NMI TA Coordination Team is planning an NMI Technical Assistance Orientation Meeting (proposed date is 2/27/2015) for all pilot jurisdictions.
At this meeting, CDC, CSTE, and APHL plan to discuss lessons learned from the Michigan NMI pilot; the changes in the HL7 message structure; available NMI TA tools, resources, and trainings; overview of the NMI TA evaluation plan; and a draft NMI TA timeline.

- The NMI team will share more details about the orientation meeting as they are finalized.

- NMI will be the topic of the 3/4/2015 Public Health Information Network (PHIN) Partner Call. On this call, NMI leadership will provide a broad overview of the information presented during the NMI TA Orientation Meeting to all jurisdictions and NMI stakeholders.

- Reminder about MMG status:
  - MMGs in Stages I, II, and III are considered draft and may be revised until the time they are finalized.
  - Those jurisdictions selected for pilot testing of the test-ready versions (Stage III) of the MMGs should wait until contacted by the NMI TA Team before using the test-ready MMGs, before implementing surveillance information system changes, and before submitting test messages to CDC.
  - All other jurisdictions should not plan to submit data to CDC or implement MMG-based updates to their surveillance information systems until the final MMGs (Stage IV) have been posted to the PHIN website.

- For more information about technical assistance:
  - For pilot jurisdictions: If you have questions specific to NMI TA, please contact Laura Carlton, contractor to APHL, at lcarlton@TSJG.com.
  - For non-pilot jurisdictions: If you have questions or would like to request TA for MMG implementation through the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Cooperative Agreement, please email edx@cdc.gov.

For more information on NMI, please see the NMI FAQs at http://wwwn.cdc.gov/nndss/script/faqs.aspx. If you have questions not answered in the FAQs, please send them to edx@cdc.gov.